Afrigen Biologics

Afrigen Biologics and Vaccines operates as a pivotal mRNA vaccine technology transfer hub in South Africa, focusing on the development and distribution of COVID-19 vaccines. The company collaborates with global health organizations to facilitate the transfer of vaccine technology from developed to developing regions, addressing the urgent need for equitable vaccine access. Afrigen's business model centers on leveraging technology partnerships to produce and supply vaccines, primarily targeting underserved markets in the Global South. Revenue is generated through technology licensing, manufacturing partnerships, and direct vaccine sales. The company serves governments, healthcare providers, and international health agencies, contributing to global health security and pandemic preparedness.

Keywords: mRNA, vaccine, technology transfer, COVID-19, South Africa, global health, manufacturing, partnerships, equitable access, pandemic preparedness.